Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BLCO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial NCT07778888 · Dry Eye Disease BL1107 | BLCO Bausch & Lomb Incorporated | Phase 2 | Recruiting was not yet recruiting | 20 | Feb 2027 | Registry ↗ |
| Nov 5, 2026 | Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2 NCT06997003 · Hyperopia and Myopia Anterior treatment mode, Anterior treatment mode | BLCO Bausch & Lomb GmbH | Not applicable | Recruiting | 81 | May 2027 | Registry ↗ |
| Oct 22, 2026 | A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pai… NCT07412496 · Pain, Postoperative Topical Ocular BL1332 low dose, Topical Ocular BL1332 high… | BLCO Bausch & Lomb Incorporated | Phase 2 | Completed | 130 | Oct 4, 2026 | Registry ↗ |
| Oct 16, 2026 | Revive Toric RWE Study NCT06785194 · Astigmatism REVIVE samfilcon B custom toric contact lenses | BLCO Bausch & Lomb Incorporated | — | Withdrawn | 0 | Mar 2026 | Registry ↗ |
| Oct 8, 2026 | Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratom… NCT05264623 · Hyperopia TENEO 317 Model 2 excimer laser | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 140 | Aug 24, 2026 | Registry ↗ |
| Sep 17, 2026 | 1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for Astigmatism NCT05320042 · Myopia, Astigmatism kalifilcon A daily disposable toric contact lenses, Ultra f… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 35 | May 10, 2022 | Registry ↗ |
| Sep 10, 2026 | A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants NCT07717918 · Healthy BL1332 eye drops, BL1332 Placebo eye drops | BLCO Bausch & Lomb Incorporated | Phase 1 | Completed | 28 | Aug 5, 2026 | Registry ↗ |
| Aug 25, 2026 | 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses NCT06053736 · Refractive Ametropia, Astigmatism REVIVE Toric Soft Contact Lenses | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 32 | Dec 15, 2023 | Registry ↗ |
| Aug 25, 2026 | Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lens… NCT05129488 · Contact Lens Wearer All participants received Biotrue ONEday lenses with and wi… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 33 | Sep 20, 2021 | Registry ↗ |
| Aug 6, 2026 | 1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Pres… NCT05325931 · Presbyopia kalifilcon A Daily Disposable Multifocal, samfilcon A for P… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 30 | Mar 28, 2022 | Registry ↗ |
| Aug 5, 2026 | Surface Refractive Index Shift of Kalifilcon A Compared With Dailies Total1 and Precision1 Lenses NCT04840563 · Contact Lens Wear kalifilcon A daily disposable spherical soft contact lens,… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 10 | Apr 15, 2021 | Registry ↗ |
| Jul 22, 2026 | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular… NCT07168902 · Glaucoma BL1107 Low dose, BL1107 High dose | BLCO Bausch & Lomb Incorporated | Phase 2 | Completed | 252 | May 18, 2026 | Registry ↗ |
| Jul 14, 2026 | A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease NCT07128628 · Dry Eye Disease Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Li… | BLCO Bausch & Lomb Incorporated | Phase 2 | Completed | 443 | May 28, 2026 | Registry ↗ |
| Jul 13, 2026 | Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in… NCT06333015 · Cataract enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 304 | Jun 11, 2026 | Registry ↗ |
| Jul 6, 2026 | A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Ref… NCT06346340 · Dry Eye Miebo | BLCO Bausch & Lomb Incorporated | Phase 4 | Completed | 97 | Feb 24, 2025 | Registry ↗ |
| Jun 3, 2026 | A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocu… NCT06594185 · Cataract enVista Aspire EA or Aspire Toric ETA IOLs | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 335 | May 21, 2025 | Registry ↗ |
| May 28, 2026 | A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With S… NCT06803654 · Ocular Redness BTOS-HA, Lumify® | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 578 | Jun 29, 2025 | Registry ↗ |
| May 26, 2026 | Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens NCT06479148 · Cataract enVista® Aspire™, An IOL with a slightly extended depth of… | BLCO Bausch & Lomb Incorporated | Not applicable | Terminated | 27 | Dec 12, 2024 | Registry ↗ |
| May 6, 2026 | A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices E… NCT06767917 · Cataract Eyefill® S.C., Eyefill® M.B. | BLCO Bausch & Lomb GmbH | Not applicable | Completed | 148 | Mar 25, 2026 | Registry ↗ |
| Jan 30, 2026 | A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Las… NCT07377474 · Myopic Astigmatism TENEO 317 Model 2 (1.28 US) Excimer Laser | BLCO Bausch & Lomb Incorporated | Not applicable | Not yet recruiting | 32 | Sep 2027 | Registry ↗ |
| Jan 27, 2026 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical… NCT06978244 · Ocular Pain BL1332 ophthalmic solution, BL1332 ophthalmic vehicle | BLCO Bausch & Lomb Incorporated | Phase 1 | Active, not recruiting | 24 | Nov 2026 | Registry ↗ |
| Jan 12, 2026 | IC-8 Apthera IOL New Enrollment Post Approval Study NCT06060041 · Cataract, Presbyopia | BLCO Bausch & Lomb Incorporated | — | Recruiting | 435 | Sep 30, 2027 | Registry ↗ |
| Dec 18, 2025 | A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear NCT07054606 · Dry Eye Perfluorohexyloctane ophthalmic solution | BLCO Bausch & Lomb Incorporated | Phase 4 | Completed | 104 | Nov 3, 2025 | Registry ↗ |
| Dec 10, 2025 | A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination i… NCT07111013 · Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) | BLCO Bausch & Lomb Incorporated | Phase 3 | Withdrawn | 0 | Apr 2027 | Registry ↗ |
| Oct 21, 2025 | A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease NCT06309953 · Dry Eye Miebo | BLCO Bausch & Lomb Incorporated | Phase 4 | Completed | 99 | Jun 17, 2024 | Registry ↗ |
| Aug 24, 2025 | Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokera… NCT05984290 · Myopia orthokeratology lens | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 90 | Jun 27, 2024 | Registry ↗ |
| Jul 20, 2025 | 2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commer… NCT05126953 · Contact Lens Wearer samfilcon A Lenses with EPG01 Packaging Solution, Commercia… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 30 | Sep 23, 2021 | Registry ↗ |
| Jul 10, 2025 | Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.0… NCT05815758 · Allergic Conjunctivitis Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophth… | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 512 | Sep 18, 2023 | Registry ↗ |
| Jul 10, 2025 | Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily… NCT05129124 · Astigmatism kalifilcon A Daily Disposable Toric LD213001 Contact Lenses… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 30 | Jan 13, 2022 | Registry ↗ |
| Jul 4, 2025 | Effects of NOV03 on the Tear Film NCT05723770 · Dry Eye Disease (DED) instillation of NOV03 | BLCO Bausch & Lomb Incorporated | Phase 4 | Completed | 33 | Dec 23, 2023 | Registry ↗ |
| Jul 1, 2025 | Orientation Characteristics of Daily Disposable Toric Contact Lenses NCT06069609 · Astigmatism kalifilcon A Daily Disposable Toric, Acuvue Oasys 1-Day for… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 30 | Aug 15, 2023 | Registry ↗ |
| Jul 1, 2025 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic… NCT05591755 · Seasonal Allergic Conjunctivitis Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Opht… | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 229 | Aug 9, 2023 | Registry ↗ |
| Jun 24, 2025 | Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric Lenses NCT05129072 · Contact Lens Wearer kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 75 | Sep 24, 2021 | Registry ↗ |
| Jun 15, 2025 | Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Ast… NCT06618547 · Myopia TENEO 317 Model 2 excimer laser | BLCO Bausch & Lomb Incorporated | Not applicable | Not yet recruiting | 140 | Nov 2026 | Registry ↗ |
| Jun 15, 2025 | A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correc… NCT06305663 · Myopia Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophil… | BLCO Bausch & Lomb Incorporated | Not applicable | Recruiting | 418 | Jan 31, 2027 | Registry ↗ |
| May 20, 2025 | A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Soluti… NCT05565937 · Refractive Ametropia BL-3100-NBR03 multi-purpose solution, renu® Advanced Formul… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 295 | Feb 28, 2024 | Registry ↗ |
| May 2, 2025 | A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extra… NCT06333028 · Cataract enVista Aspire EA IOLs | BLCO Bausch & Lomb Incorporated | — | Completed | 82 | Mar 13, 2025 | Registry ↗ |
| Mar 27, 2025 | Safety and IOP-Lowering Effects of WB007 NCT04149899 · Glaucoma, Primary Open Angle, Ocular Hypertension WB007 0.05%, WB007 0.15% | BLCO Bausch & Lomb Incorporated | Phase 1/2 | Completed | 77 | Jan 31, 2021 | Registry ↗ |
| Feb 14, 2025 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Con… NCT05579730 · Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brim… | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 188 | Jul 22, 2023 | Registry ↗ |
| Dec 24, 2024 | Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intrao… NCT03603600 · Cataract enVista MX60E, enVista MX60EF | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 501 | May 4, 2023 | Registry ↗ |
| Dec 17, 2024 | A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) A… NCT06565650 · Dry Eye Miebo, Saline | BLCO Bausch & Lomb Incorporated | Phase 4 | Active, not recruiting | 216 | Nov 2025 | Registry ↗ |
| Dec 10, 2024 | Kalifilcon A Toric Compared to Commercially Available Lenses NCT06098937 · Astigmatism Kalifilcon Toric Lens, Total1 for Astigmatism | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 30 | Sep 27, 2023 | Registry ↗ |
| Oct 23, 2024 | Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated… NCT04139798 · Dry Eye Disease (DED) NOV03, Placebo | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 599 | Mar 12, 2021 | Registry ↗ |
| Oct 10, 2024 | Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic… NCT04224155 · Cataract enVista MX60EFH trifocal intraocular lenses (IOLs), enVista… | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 165 | Jun 14, 2022 | Registry ↗ |
| Oct 8, 2024 | Evaluation of Ocular Comfort With ISTA Tears vs Systane NCT01650584 · Dry Eye Disease ISTA Tears, Systane | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 35 | Dec 2012 | Registry ↗ |
| Aug 26, 2024 | "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Re… NCT05360784 · Ocular Redness Brimonidine tartrate ophthalmic solution 0.025% preservativ… | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 380 | Nov 23, 2022 | Registry ↗ |
| Aug 19, 2024 | Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunctio… NCT04567329 · Dry Eye Disease NOV03, Saline Solution | BLCO Bausch & Lomb Incorporated | Phase 3 | Completed | 620 | Aug 30, 2021 | Registry ↗ |
| Jul 10, 2024 | A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop NCT04175340 · Contact Lens Wear BL-300-PFM04, OPTI-FREE | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 369 | Feb 17, 2020 | Registry ↗ |
| Jun 14, 2024 | A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic… NCT04111757 · Myopia, Myopic Astigmatism Technolas® TENEO 317 Model 2 | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 168 | Aug 6, 2021 | Registry ↗ |
| May 28, 2024 | A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50 NCT04192630 · Cataract CVisc50 OVD, ProVisc OVD | BLCO Bausch & Lomb Incorporated | Not applicable | Completed | 390 | Jan 31, 2022 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances